Human EPOR-JAK2 Stable Cell Line - Ba/F3

The erythropoietin receptor (EPOR) is a transmembrane protein belonging to the cytokine receptor superfamily. Upon binding to erythropoietin (EPO), EPOR undergoes a conformational change that activates the associated Janus kinase 2 (JAK2), a cytoplasmic tyrosine kinase that initiates downstream signaling cascades including the JAK2-STAT5, PI3K-AKT, and MAPK pathways. This signaling axis is essential for erythroid progenitor cell survival, proliferation, and differentiation, and its dysregulation is implicated in various hematological disorders such as polycythemia vera, primary myelofibrosis, and certain erythroleukemias. The Human EPOR-JAK2 Stable Cell Line - Ba/F3 is generated by stably transfecting the murine IL-3-dependent pro-B cell line Ba/F3 with expression constructs encoding human EPOR and JAK2. Ba/F3 cells are naturally IL-3 dependent and do not express endogenous EPOR, making them an ideal null background for studying exogenous cytokine receptor signaling. Expression of human EPOR and JAK2 in these cells enables EPO-dependent proliferation, effectively replacing the IL-3 requirement and providing a clean, controllable system for functional studies.

This cell line is widely used in preclinical drug discovery and basic research applications. It serves as a valuable tool for screening and characterizing small molecule inhibitors targeting JAK2, particularly those designed for the treatment of myeloproliferative neoplasms and other JAK2-driven malignancies. Researchers can evaluate compound potency, selectivity, and cytotoxicity by monitoring EPO-dependent cell proliferation using standard viability assays such as MTT, CellTiter-Glo, or Alamar Blue. The cell line is also suitable for mechanistic studies of JAK2 signal transduction, including phosphorylation profiling of downstream effectors like STAT5, STAT3, and ERK1/2 via western blotting or ELISA-based readouts. Additionally, it can be used to assess the functional impact of EPOR or JAK2 mutations identified in patient samples, or to study resistance mechanisms that arise under therapeutic pressure. Beyond oncology, the cell line supports research into EPO biology, erythropoiesis regulation, and the development of biosimilar EPO therapeutics.